Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 3147Triple Negative Breast Neoplasms 515Ovarian Neoplasms 230Colorectal Neoplasms 192Carcinoma, Non-Small-Cell Lung 190Prostatic Neoplasms 184Neoplasms 177Lung Neoplasms 165Neoplasm Metastasis 164Melanoma 119Stomach Neoplasms 114Pancreatic Neoplasms 113Endometrial Neoplasms 107Uterine Cervical Neoplasms 95Squamous Cell Carcinoma of Head and Neck 88Head and Neck Neoplasms 82Colonic Neoplasms 82Carcinoma, Intraductal, Noninfiltrating 82Sarcoma 63Breast Carcinoma In Situ 62Carcinoma, Renal Cell 61Urinary Bladder Neoplasms 60Motor Activity 59Esophageal Neoplasms 58Brain Neoplasms 50Lymphedema 44Breast Cancer Female 41Advanced Breast Cancer 40Liver Neoplasms 39HER2-positive Breast Cancer 38

Interventions

Letrozole 2palbociclib 1Fulvestrant 1Diet, Ketogenic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Estrogen Receptor-positive Breast Cancer × Breast × 1 year × Clear all
NCT03962647 2026-04-30

A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase EARLY_PHASE1 Completed
31 enrolled
Breast

Estrogen Receptor-positive Breast Cancer

NCT03633331 2026-04-29

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
93 enrolled 16 charts
Breast

Estrogen Receptor-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡